Home › Conditions › Atrial Fibrillation — Fast Ventricular Rate
cardiology
Atrial Fibrillation — Fast Ventricular Rate
In AF with rapid ventricular rate, first assess haemodynamic stability. Unstable (SBP <90, chest pain, syncope, acute pulmonary oedema) → DC cardioversion. Stable → rate control first. Always look for a precipitant.
AF Rate/Rhythm Control
The pathway
1 · Assess haemodynamic status
- SBP <90, chest pain, syncope, or acute pulmonary oedema → UNSTABLE
- Immediate DC cardioversion (synchronised 120–200J biphasic). Call anaesthetics.
2 · Stable: Rate control
- Bisoprolol 2.5–5mg PO or metoprolol 2.5mg IV slow bolus
- Or diltiazem if beta-blockers contraindicated
- Target HR <110 at rest.
3 · Find the cause
- Infection/sepsis
- Electrolyte abnormalities (K+, Mg)
- Thyrotoxicosis
- PE
- MI
- Alcohol
Treat the underlying cause.
4 · Anticoagulation decision
- CHA₂DS₂-VASc ≥2 (men) or ≥3 (women): start anticoagulation
- If AF >48h: anticoagulate ≥3 weeks before rhythm control, or TOE to exclude thrombus.
5 · Rhythm control
If AF onset <48h and haemodynamically stable: consider pharmacological cardioversion (flecainide 300mg PO if no structural heart disease, or amiodarone IV).
6 · Electrolytes
- Correct K+ (target >4 mmol/L)
- Mg (1–2g IV MgSO₄ if low).
Drugs
| Drug | Dose | Route | Notes |
|---|---|---|---|
| Bisoprolol | 2.5–5mg | PO | Rate control. Avoid in asthma, decompensated HF. |
| Metoprolol | 2.5mg | IV | Slow bolus. Can repeat. Rate control in acute setting. |
| Digoxin | 500mcg | IV | Rate control if beta-blockers contraindicated (e.g. severe HF). Slow onset. |
| Amiodarone | 300mg over 1h then 900mg over 23h | IV | Rhythm control. Use in structural heart disease. |
| Flecainide | 300mg | PO | Rhythm control. ONLY if no structural heart disease or coronary disease. |
| Apixaban | 5mg BD | PO | Anticoagulation. Reduce to 2.5mg BD if 2/3 criteria: age≥80, weight≤60kg, Cr≥133. |
When to escalate
Haemodynamic instability → immediate DC cardioversion,Suspected WPW (irregular broad complex) → do not use AV nodal blockers,Refractory rate despite dual rate control agents,New onset in ACS or post-cardiac surgery
Reference: ESC AF Guidelines 2023 / NICE NG196
This page is the reference half
The app adds what a web page cannot: a VINDICATE differential builder, worked on-call scenarios with full A–E findings, recall practice, and all of it offline.